Highest-materiality recent filing
Minerva enters $75M ATM offering; Phase 3 roluperidone relapse phase extended to 52 weeks
Up to $75M in common stock may be sold at-the-market through Leerink Partners; 3% commission.
Minerva Q1 GAAP net loss $125.4M on warrant revaluation; Phase 3 roluperidone trial advances
Confirmatory Phase 3 trial of roluperidone for negative symptoms of schizophrenia initiated; first patient screened March 2026; topline data expected 2H 2027.
Minerva (NERV) Q4 non-GAAP adj loss $7.1M; cash $82.4M; Phase 3 roluperidone on track for Q2 2026
Non-GAAP adjusted net loss for Q4 2025 was $7.1M ($0.64/sh) vs $4.0M ($0.53/sh) in Q4 2024.
Minerva unveils Phase 3 trial design for roluperidone; planned start Q2 2026
Phase 3 trial to enroll 380 patients with negative symptoms of schizophrenia; 1:1 randomization to placebo or 64 mg roluperidone.
Dr. Kaul appointed to Minerva's board (Class II) effective Nov 14, 2025; board size increased to 6.
Minerva Neurosciences raises up to $200M to fund Phase 3 trial of roluperidone
Private placement: $80M upfront Series A preferred; Tranche A warrants for another $80M (cash exercise), Tranche B warrants for $40M contingent on milestone event.
Minerva Neurosciences regains Nasdaq compliance with net income rule
Nasdaq Panel confirmed compliance with Listing Rule 5550(b)(3) (minimum $500K net income from continuing operations).
Nasdaq Panel grants Minerva continued listing subject to equity compliance by March 31, 2025
Company must file disclosure on transactions to meet $2.5M minimum stockholders' equity by 3/31/25.
Minerva Neurosciences receives Nasdaq delisting notice for MVLS non-compliance; to request hearing
Second Nasdaq notice for continued non-compliance with $35M minimum Market Value of Listed Securities; delisting determination unless hearing requested.
Minerva Neurosciences receives Nasdaq delisting notice for low market value
MVLS below $35M minimum for 31 consecutive business days as of April 10, 2024.
FDA issues Complete Response Letter for roluperidone; NDA not approved
FDA cited single positive study insufficient; requires at least one additional positive well-controlled trial.
Minerva Neurosciences raises $20M in PIPE at $10/share for roluperidone launch
Gross proceeds ~$20M from 1,425,000 shares at $10/share and 575,575 pre-funded warrants at $9.99.
Minerva Neurosciences regains Nasdaq compliance on minimum market value requirement
Received Nasdaq Compliance Notice on June 16, 2023, after MVLS exceeded $35M for 10 consecutive business days.
On May 29, 2024, Jeryl Hilleman notified the Board of Directors (the “Board”) of Minerva Neurosciences, Inc. (the “Company”) of her intention to resign as a member of the Board, effective August 6, 2024, including from her role as Chair of the Audit Committee of the Board.
Max materiality 1.00 · Median 0.60 · Most common event other_material